scorecardresearch
Thursday, November 7, 2024
Support Our Journalism
HomeDiplomacyPiyush Goyal & United States Trade Representative discuss TRIPS waiver and vaccine...

Piyush Goyal & United States Trade Representative discuss TRIPS waiver and vaccine production

In a virtual meeting, USTR Katherine Tai reaffirmed the United States' commitment to help India. And stated her support for the waiver of IP protections for Covid-19 vaccines.

Follow Us :
Text Size:

Washington: Union Commerce and Industry Minister Piyush Goyal discussed the proposed waiver to provisions of the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for COVID-19-specific items and raising vaccine production with United States Trade Representative (USTR), Katherine Tai, in a virtually meeting on Friday.

During the meeting, Tai conveyed her deep sympathy for the people of India as the country battles a deadly wave of COVID-19 and reaffirmed the commitment of the United States to help India, the USTR said in a readout of the call.

India is in the midst of a deadly wave of the coronavirus pandemic, with 3,43,144 people testing positive for the virus on Friday, taking the country’s caseload to 2,40,46,809. The death toll stands at 2,62,317.

India’s COVID-19 tally crossed the 10 million mark on December 19 and in under six months it has doubled, surpassing the grim milestone of 20 million cases on May 4.

Tai explained her support for the waiver of intellectual property (IP) protections for COVID-19 vaccines and text-based negotiations at the WTO, which are part of the Joe Biden administration’s comprehensive effort to expand vaccine manufacturing and distribution around the world.

Tai recognised the WTO members who have expressed support for future negotiations and welcomed an update from Goyal on India’s efforts to revise and re-submit their waiver proposal, the release said.

India and South Africa have been pushing a resolution at the WTO that would force pharmaceutical companies to hand over their COVID-19 vaccine and therapy IP to manufacturers in low-income countries. The waiver is backed by nearly 100 other low-income countries, progressive groups and more than 100 Democratic Congress members.


Also read: ZyCoV-D could be India’s next Covid vaccine: Learn the science behind it & how it’s different


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular